Estimaciones de analistas de Wall Street para NeoGenomics, Inc. (NEO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 1 |
| Compra | 22 |
| Mantener | 5 |
| Venta | 1 |
| Venta fuerte | 0 |
| Analistas totales | 29 |
| Calificación media (1-5) | 0.79 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-27 | $0.06 | ||
| 2026-07-28 | $0.05 | $0.03 | +49.0% |
| 2026-04-28 | $0.01 | $0.01 | +73.0% |
| 2026-02-17 | $0.06 | $0.04 | +50.0% |
| 2025-10-28 | $0.03 | $0.02 | +50.0% |
| 2025-07-29 | $0.03 | $0.03 | +0.0% |
| 2025-04-29 | $-0.08 | $-0.02 | -300.0% |
| 2025-02-18 | $0.04 | $0.03 | +33.3% |
Ratios de valoración
| Precio / Valor contable | 0.66 |
| EV / EBITDA | 58.16 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $244.1M | $240.3M | $276.7M | $408.8M | $444.4M | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Coste de Ventas | $133.7M | $138.3M | $149.5M | $212.0M | $258.6M | $297.3M | $321.8M | $347.0M | $370.5M | $444.8M |
| Beneficio Bruto | $110.4M | $102.0M | $127.3M | $196.8M | $185.9M | $187.1M | $187.9M | $244.6M | $290.1M | $282.5M |
| I+D | $4.6M | $3.6M | $3.0M | $8.5M | $8.2M | $21.9M | $30.3M | $27.3M | $31.2M | $37.1M |
| Generales y Administrativos | $87.8M | $113.3M | $114.2M | $175.3M | $191.7M | $283.9M | $277.9M | $280.0M | $310.5M | $365.3M |
| Gastos Operativos | $95.9M | $99.1M | $117.2M | $183.8M | $199.9M | $305.8M | $345.5M | $352.3M | $382.2M | $348.6M |
| Beneficio Operativo | $2.6M | $2.9M | $10.0M | $13.0M | -$14.0M | -$118.8M | -$157.6M | -$107.7M | -$92.1M | -$66.1M |
| EBITDA | $25.4M | $26.6M | $31.8M | $37.6M | $34.9M | $46.5M | -$82.3M | -$17.6M | -$1.5M | -$38.7M |
| Gastos por Intereses | $10.0M | $5.5M | $6.2M | $3.7M | $7.0M | $8.2M | $7.6M | $6.9M | $6.6M | $3.8M |
| Beneficio Antes de Impuestos | -$7.4M | -$2.6M | $3.8M | $3.6M | -$14.1M | -$15.1M | -$159.3M | -$97.1M | -$80.7M | -$110.3M |
| Impuestos | -$1.7M | -$2.3M | $1.2M | -$4.4M | -$18.2M | -$6.7M | -$15.1M | -$9.1M | -$1.9M | -$2.2M |
| Beneficio Neto | -$6.1M | -$396000 | $2.6M | $8.0M | $4.2M | -$8.3M | -$144.2M | -$88.0M | -$78.7M | -$108.0M |
| BPA | $-0.40 | $-0.03 | $0.14 | $0.40 | $0.19 | $-0.35 | $-5.80 | $-3.50 | $-3.10 | $-4.20 |
| BPA Diluido | $-0.40 | $-0.03 | $0.14 | $0.39 | $0.19 | $-0.35 | $-5.80 | $-3.50 | $-3.10 | $-4.20 |
| Acciones en Circulación (Diluidas) | $15.5M | $15.9M | $18.3M | $20.7M | $22.4M | $24.0M | $24.8M | $25.1M | $25.3M | $25.6M |
Precio
| Precio | $19.62 |
| Capitalización | $504M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACRS · ARCT · HUMA · MDXH · QTRX · SGMT · SMTI
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de NEO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones